Kornimate/medical-research-clean huggingface dataset:
evaluate recovery of testosterone for patients using eligard

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine if testosterone will recover to 90% by year 1 after using eligard.

this is a multi-center, open-label study to evaluate testosterone recovery after six months of neo-adjuvant treatment with eligard (tm) 22.5mg used with radiation therapy in patients with tnm t1, t2 or t3a adenocarcinoma of the prostate. the 60 patients will receive two subcutaneous administration of eligard (tm) 22.5mg (baseline and month 3) and receive radiation therapy (month 2-4).

Eligibility criteria:
inclusion criteria: * must be outpatient, not hospitalized * male patient between ages 50-80, inclusive * histologically/cytologically graded adenocarcinoma of the prostate * must have t1, t2 or t3a adenocarcinoma of the prostate * must be a candidate for radiation therapy. hormone refractory patients excluded * who/ecog score of 0,1 or 2 exclusion criteria: * no evidence of urinary tract that would put the patient at risk in the opinion of the investigator. * used the following treatments for prostate cancer \*immunotherapy \*chemotherapy \*external beam radiation \*brachytherapy \*hormonal therapy \*biological response modifiers * prior prostate surgery (excluding tuna or turp) * undergone orchiectomy, adrenalectomy, hypophysectomy or be receiving any product which could alter the function of these organs * use of investigational drug, biologic or device within five half-lives of its physiological action or three months prior to base line, whichever is longer * over the counter or alternative medical therapies which have estrogenic or anti-androgenic effect * uncontrolled chf within 6 months to baseline * myocardial infarct, coronary vascular procedure or clinically significantcardiovascualr disease within 6 months of baseline visit * venous thrombosis with in 6 months of screening * uncontrolled hypertension defined as \>170/100 or symptomatic hypotension within 3 months of baseline * insulin dependant diabetic patients must not administer in an anatomic region where they will receive eligard. * drug or alcohol abuse 6 months prior to baseline * other serious illness at the discretion of the investigator * patients receiving anti-coagulant or anti-platlet medication must be on a stable dose for 3 months prior to baseline * hypersensitivity to gnrh, gnrh agonists

Keywords: prostate cancer
prevention of intrathecal morphine induced pruritus: comparison of ondansetron and palonosetron

Conditions: Morphine Adverse Reaction

Summary: intrathecal administration of morphine is often used for control of postoperative pain. however, pruritus is one of the most common side effects of intrathecal morphine . specific serotonin receptor antagonists could be an effective prophylactic treatment of neuraxial opioid-induced pruritus. it was reported that palonosetron is more effective than ondansetron for prevention of postoperative nausea and vomiting. therefore, the investigators evaluated the efficacy of prophylactic administration of ondansetron and palonosetron for the prevention of intrathecal morphine-induced pruritus.

intrathecal administration of morphine is often used for relief of postoperative pain. however, pruritus is one of the most common side effects associated with intrathecal morphine. specific serotonin receptor antagonists such as ondansetron could be an effective prophylactic treatment of neuraxial opioid-induced pruritus. it was reported that palonosetron is more effective than ondansetron for prevention of postoperative nausea and vomiting. therefore, the investigators evaluated the efficacy of prophylactic administration of ondansetron and palonosetron for the prevention of intrathecal morphine-induced pruritus.

Eligibility criteria:
inclusion criteria: * 19-70 years, * american society of anesthesiology physical status 1 and 2 * scheduled for elective urologic surgery under spinal anesthesia. exclusion criteria: * patients with cardiac and psychological problems. * patients who take sedatives or narcotics. * patient who have allergy to study drugs.

Keywords: intrathecal morphine ondansetron palonosetron pruritus
video-laryngoscopy during chest compression

Conditions: Cardiac Arrest; Intubation, Endotracheal

Summary: the investigators will compare the success rates and time to successful intubation of endotracheal intubation during simulated pediatric and infant resuscitation with and without chest compression using four different video-laryngoscopes.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * minimum 1 year of work experience in nursing exclusion criteria: * not meet the above criteria * wrist or low back diseases
greater occipital nerve block versus pulse radiofrequency in migraine

Conditions: Migraine

Summary: the aim of the study is to evaluate the clinical efficacy of the repeated greater occipital nerve(gon) blokcs with gon pulse radiofreaquency (prf)

the nerve blocks will be performed at the cervical-2 (c2) level with ultrasound guidance.also , the prf will be done as above proximally.

Eligibility criteria:
inclusion criteria: * ichd- migraine with minimum 4 attacks * no benefit with proflactic therapies exclusion criteria: * primary headhache other than migraine according to ichd * the change of medical teatment of migrane in last 1 month.

Keywords: migraine greater occipital nerve block pulse radiofrequency
the effectiveness of brain-computer interface-pedaling training system on the rehabilitation of stroke

Conditions: Rehabilitation; Stroke; Brain-computer Interface

Summary: stroke has become the first cause of death and disability among chinese adults. 70%-80% of patients cannot live independently due to disability, which has brought a heavy burden to families, medical institutions and society. how to better evaluate and improve post-stroke motor and cognitive dysfunction has always been a hot research topic. with the rapid development of brain-computer interface technology, rehabilitation assessment based on quantitative eeg analysis is gradually being applied in the medical field. so we designed a brain-computer interface based on hierarchical task induction-pedaling rehabilitation training system to investigate the effectiveness on the rehabilitation of stroke patients.


Eligibility criteria:
inclusion criteria: * aged 40-80 years old； * patients with first ischemic stroke onset from 1 week to 3 months； * hemiplegia and cognitive impairment (mini-mental state examination (mmse) score \<28 or montreal cognitive assessment (moca) \<25)； * consciousness, sitting balance level 1 or above, can cooperate with assessment and treatment; * the patient or its authorized agent signs the informed consent form. exclusion criteria: * severely impaired cognition, unable to pay attention to and understand screen information; * severe pain and limited mobility of lower extremity.
tissue inhibitor of metalloproteinases 2 level in patients undergoing cardiac surgery

Conditions: Acute Kidney Injury; Extracorporeal Circulation; Complications; Surgery

Summary: acute kidney injury (aki) is one of the most frequent major complications in patients undergoing cardiac surgery. csa-aki is independently related to increased perioperative mortality, increased hospital and icu length of stay as well as heath care expenditure. identification of relevant biomarkers may lead to early diagnosis and improve patient outcomes and health care costs. the pathophysiology of csa-aki is complex and ischemia-reperfusion injury is one of the important factors. recently, it has been shown that tissue inhibitor of metalloproteinases 2 (timp2) is associated with ischemia-reperfusion injury. in this study, relationship between timp2 with the risk of csa-aki was analyzed and the predictive value of elevated level of timp2 for early prediction of csa-aki was further evaluated.


Eligibility criteria:
inclusion criteria: * patients (≥18 years old) underwent on-pump cardiac surgery * admitted to icu immediately after surgery exclusion criteria: * patients younger than 18 years * with prior aki * end-stage kidney disease * need for chronic hemodialysis * pregnant patients * unable to give written consent for participation
exercise effect on transthyretin stability

Conditions: Amyloidosis Transthyretin; Athlete Heart

Summary: the goal of this study to investigate if exercise predisposes to transthyretin instability. the investigators will evaluate the effect of exercise on transthyretin biochemistry.

this is an investigator initiated observational study, designed to study the effect of exercise on transthyretin stability in three main populations: group 1: healthy master athletes who are 60 years or older. group 2: genotype positive (g+) cardiac phenotype negative (p-) patients with variant attr (i.e. carriers without evidence of disease). group 3: patients with attr ca who have not been on a stabilizer (tafamidis) within the last 14 days prior to enrollment.

Eligibility criteria:
inclusion criteria: general inclusion criteria: patients should be able to exercise on a treadmill or a bike, willing to consent to the study procedures and willing to return to site during the follow up period of 72 hours for repeated blood and urine collection specific inclusion criteria: * group 1: subjects must be at least 60 years of age and meet the master athlete definition of: athletes engaged in cycling ≥8 hours per week or running ≥6 hours per week or triathlon training (combination of swimming, cycling, running) ≥8 hours per week, or equivalent sports activities, for at least 6 months prior to enrollment. * group 2: genotype positive (g+) cardiac phenotype negative (p-) patients with variant attr (i.e. carriers without evidence of disease) * group 3: patients with attr ca who have not been on a stabilizer (tafamidis) within the last 14 days prior to enrollment. exclusion criteria: taking diflunisal or daily non-steroidal anti-inflammatory drugs (nsaids) use within 2 weeks.

Keywords: exercise amyloidosis
collection of blood from healthy patients, patients with benign disease and patients with cancer

Conditions: Cancer; Liver Cirrhosis; Chronic Hepatitis; Hepatitis B; Hepatitis C; Diabetes; COPD

Summary: to acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select dna methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.

whole blood, plasma, and/or serum specimens will be collected from patients with active cancer, patients in cancer remission, patients diagnosed with benign disease, and healthy volunteers. these blood samples will be used to perform various studies to determine the utility of select dna methylation markers for cancer diagnostic or prognostic indications.

Eligibility criteria:
inclusion criteria: 2.1.1 age 18 years or older. 2.1.2 a diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis b or hepatitis c virus infection, chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. . exclusion criteria: 2.2.1 patients that are unwilling or unable to sign the informed consent form will be excluded. 2.2.2 approximately 50 ml of blood will be drawn from participants within an 8-week period under this protocol. patients that have already given 50 ml of blood within this time frame will be excluded.
natrecor for pulmonary hypertension in lung transplants

Conditions: Pulmonary Hypertension

Summary: this study seeks to demonstrate that natrecor® (nesiritide) is safe and effective and has a favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance of inhaled nitric oxide (ino) use. it is estimated that the use of nesiritide will decrease the otherwise historically mandated use of ino by 50%, as compared to the necessity of ino use by matched historical controls.

a condition called ischemic reperfusion injury (iri) occurs in all lung transplants. the amount of reperfusion injury varies from person to person. iri occurs when the blood supply to tissue (in this case, transplanted lung(s)) is decreased and then is restored. iri can cause a decrease in function in a newly transplanted lung. when this occurs, or when people have pulmonary hypertension (high blood pressure in your lungs), doctors use nitric oxide to improve the pressure and blood supply to the transplanted lung. nitric oxide (no) is given by inhalation while patients are on a ventilator (breathing machine). because no must be given by a ventilator and because patients on ventilators must be in an intensive care unit, the cost of treating people with no is very high. no can also cause rebound pulmonary hypertension (high blood pressure in the lungs that reoccurs) when it is stopped. because of these reasons, doctors are looking for other treatments for iri and pulmonary hypertension. a drug called natrecor has been shown to reduce pulmonary pressures in heart transplant patients. doctors believe it may be helpful to lung transplant patients as well.

Eligibility criteria:
inclusion criteria: * single or double lung transplant or heart/lung transplant recipient * planned use of natrecor * pulmonary artery (pa) systolic pressures \> 35 exclusion criteria: * previous lung transplant * use of prolastin after pneumonectomy * mean arterial pressure of \< 55 * known allergy or sensitivity to nesiritide * females of childbearing potential with a positive pregnancy test or women who are breast feeding * use of nesiritide, for any reason, within 30 days prior to transplant

Keywords: pulmonary hypertension in lung transplant recipients
local anesthetic treatment of oral pain in patients with mucositis

Conditions: Mucositis

Summary: oral mucositis is a damage to the mucosa of the oral cavity and pharynx. it is a serious and painful adverse effect caused by the radio therapy and/or chemo therapy patients with head and neck cancer receive. the pain caused by oral mucositis can be difficult to treat as the current treatment with opioids is not sufficient and can cause adverse effects. our hypothesis is that treatment with a local anesthetic lozenge with bupivacaine can reduce the oral pain caused by mucositis compared with the current standard treatment.


Eligibility criteria:
inclusion criteria: * diagnosed with head/neck cancer and starting radio therapy treatment * age between 18 and 80 years (both included) * able to talk, read and understand danish * ability to give informed consent exclusion criteria: * known hypersensitivity towards bupivacaine or other local anesthetics of the amide type * pregnancy * women breastfeeding a child

Keywords: anesthetics, local bupivacaine lozenge administration, topical
ketone ester supplementation on neuro-cardiovascular responses to stress in humans

Conditions: Ketosis

Summary: ketone ester supplementation has become increasingly popular as an athletic supplement. however, the metabolic effects of these supplements on exercise performance are controversial. one potential reason for lack of an ergogenic benefit could be the effects of ketone bodies on other bodily systems, such as the sympathetic nervous system. during exercise and stress the body increases the activity of the sympathetic nervous system. this causes blood vessels to constrict (get smaller) and can increase blood pressure. studies have shown that ketone bodies can suppress the sympathetic nervous system in mice. additionally, ketone ester supplementation can reduce blood pressure in healthy adults. in humans, direct measures of sympathetic activity are usually made from sympathetic outflow to muscle, also called muscle sympathetic nerve activity (msna). using a ketone ester supplement, the investigators plan to measure blood pressure and sympathetic outflow to muscle at rest and during handgrip exercise and a mathematical task stress test to investigate the effect of ketones on neuro-cardiovascular stress responses.


Eligibility criteria:
inclusion criteria: * 18 to 40 years of age * healthy, free of known cardiovascular, metabolic, or musculoskeletal disease exclusion criteria: * history of smoking (within 3 months), diagnosed cardiovascular or metabolic disease, recent musculoskeletal injury preventing handgrip exercise, prescription of chronic medications other than oral contraceptives. * current or recent (within 6 months) use of ketone ester supplementation or participation in a ketogenic diet. * inability to abstain from drugs, caffeine, alcohol, or strenuous physical activity prior to the study visit.
evaluation of the prognostic impact of a neuro-vascular examination associated with cerebral mri in the acute phase of infectious endocarditis

Conditions: Endocarditis; Stroke

Summary: infectious endocarditis (ie) is a serious condition with an annual incidence of 3 to 10 per 100,000 people. brain infarctions complicate approximately 20-40% of endocarditis. brain mri can detect the presence of recent ischemic lesions and asymptomatic microbleeds. preoperative brain imaging is part of the recommended assessment in the management of ies, but the type of imaging and sequences are not codified and the impact of cerebral and vascular imaging findings on the therapeutic decision remains uncertain. the level of evidence of the recommendations remains low, especially for complicated ies of stroke. there is very little neurological clinical data on patients with ies. similarly, neurologists do not systematically participate in multidisciplinary meetings during the management of an ie. it therefore seems interesting to carry out a neurological cohort of this population and to evaluate what would be the contribution of vascular neurologists in the management of infectious endocarditis.


Eligibility criteria:
inclusion criteria: * adult patients * certain infectious endocarditis according to dukes criteria * signed informed consent exclusion criteria: * hospital admission due to neurovascular emergency * mri contraindications * pregnant or women of childbearing age who were not using contraception (oral diagnosis), * patient without health coverage, * patient under legal protection.

Keywords: neurological assessment medical care
intravitreal bevacizumab and low fluence photodynamic therapy

Conditions: Myopia

Summary: the purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (ivb) and photodynamic therapy (pdt) with verteporfin using a reduced (rf) light fluence rate, in choroidal neovascularization (cnv) secondary to pathologic myopia.

in this retrospective interventional case series, 16 patients with myopic cnv were included. all patients were treated with 1.25 mg of intravitreal bevacizumab followed by rf-pdt (25 j/cm²), 2 days later. all patients were previously treated with ivb monotherapy and active leaking of cnv occurred 90 to 120 days after the treatment. best-corrected visual acuity (bcva-etdrs), foveal thickness (ft) on optical coherence tomography (oct), and fluorescein and indocyanine green angiographic (fa; icg) findings were recorded. follow-up evaluations were carried out for 12 months.

Eligibility criteria:
inclusion criteria: * myopic cnv, cnv leakage exclusion criteria: * cnv not associated with high myopia * no activity of cnv
confocal laser endomicroscopy guided cryobiopsy in the diagnosis of interstitial lung disease

Conditions: Solitary Pulmonary Nodule; Multiple Pulmonary Nodule

Summary: a prospective multicenter randomized controlled trial was conducted to evaluate the diagnostic efficacy and safety of ncle-nb-rebus-guided peripheral pulmonary nodule biopsy, and to compare the diagnostic efficacy and safety of biopsy forceps biopsy and needle aspiration biopsy in peripheral pulmonary nodule biopsy guided by ncle-nb-rebus.

a prospective, multicenter, randomized controlled trial was conducted to evaluate the diagnostic efficacy and safety of ncle-nb-rebus guided peripheral pulmonary nodule biopsy. patients with peripheral pulmonary nodules suspected of lung cancer and pulmonary tuberculosis were enrolled to sign informed consent. subjects were randomized to the ncle-nb-rebus group (group a) or the nb-rebus group (group b) subgroup (1:1 ratio) according to the random number table, and subjects randomly assigned to group a or group b were again randomized to the biopsy forceps subgroup or biopsy needle subgroup by the random number table. the diagnostic efficacy and safety of the ncle-nb-rebus group and the nb-rebus group were compared to evaluate whether ncle could improve the diagnostic rate of nb-rebus-guided peripheral pulmonary nodule biopsy. the diagnostic efficacy and safety of using biopsy forceps and biopsy needle in peripheral pulmonary nodule biopsy guided by ncle-nb-rebus were compared to determine the reasonable biopsy method.

Eligibility criteria:
inclusion criteria: * patients with peripheral pulmonary nodules suspected of lung cancer by ct examination * patients who intend to undergo a bronchoscopic lung biopsy to determine benign or malignant pulmonary nodules; * age ≥18 years * sign informed consent. exclusion criteria: * there is an uncorrectable coagulation disorder or anticoagulation therapy that cannot be stopped before surgery; * tumors can be seen in the bronchus * hemodynamic instability; * refractory hypoxemia; * patients with pregnant and lactating patients * any illness or condition that interferes with the completion of the initial or subsequent assessment.
a study of prexasertib (ly2606368) in participants with advanced cancer

Conditions: Advanced Cancer

Summary: the main purpose of this study is to evaluate the safety of the study drug known as prexasertib (ly2606368) in participants with advanced cancer or cancer that has spread to other parts of the body. this study will involve a single dose of ¹⁴c radiolabelled prexasertib . this means that a radioactive substance, carbon 14, will be incorporated into the study drug. this will provide information about the study drug and its breakdown products and will help determine how much passes from the blood into urine, feces and expired air. after a minimum 14-day washout period following the \[¹⁴c\] prexasertib dose, participants will be allowed to receive continued access to prexasertib as outpatients.


Eligibility criteria:
inclusion criteria: * have a histological or cytological diagnosis of cancer (solid tumour), with clinical or radiologic evidence of locally advanced and/or metastatic disease, for which no life-prolonging therapy exists * have the presence of measurable and/or nonmeasurable disease as defined by the response evaluation criteria in solid tumours * have body surface area (bsa) greater than or equal to (≥)1.62 meter squared (m²) and less than or equal to (≤) 1.90 m² * have adequate organ function * have a performance status of ≤2 on the eastern cooperative oncology group (ecog) scale * have an estimated life expectancy, in the judgment of the investigator, that will permit the participant to complete 1 full cycle of treatment (beyond the initial \[¹⁴c\]prexasertib dose) exclusion criteria: * have received treatment within 28 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device * have serious pre-existing medical conditions (left to the discretion of the investigator) * have symptomatic central nervous system (cns) malignancy or metastasis (screening not required) * have current haematologic malignancies or acute or chronic leukaemia * have an active fungal, bacterial, and/or known viral infection * have participated in a ¹⁴c (carbon) study within the last 6 months prior to screening for this study * have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results